TrialThe AAPS journal2017

Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.

Kelong Han et al.PubMed ↗Publisher ↗

No numbers read from the abstract.